4 Ways to Own Anthropic Before It Goes Public

Corporate Action
โดย The Motley Fool·Read original
Summary · why it matters

Anthropic, the developer of the Claude chatbot, filed a confidential S-1 draft with the SEC on June 1, signaling a forthcoming IPO that could be one of the largest in history after its late-May fundraising round valued the company at $965 billion. Investors seeking early exposure can buy shares of major backers Amazon and Alphabet, which hold estimated stakes of 15% to 20% and about 14%, respectively. The KraneShares Artificial Intelligence and Technology ETF invests in both public and private companies, with Anthropic as its largest private holding at roughly 1.7% of net assets and an annual fee of 0.99%. The ARK Venture Fund, a closed-end fund, offers greater private-company exposure with Anthropic at about 6.4% of the fund and OpenAI at 8.5%, though it charges a gross annual fee of 3.49% and has higher minimums. The most direct but exclusive route is buying Anthropic shares on the secondary market, an option typically limited to professional investors and high-net-worth individuals due to high fees, minimums, and trading complexities.

Impact on stocks 2

Artificial Intelligence▲ · 2 stocks
Amazon.com Inc
AMZN
▲ PositiveCapitalrelevance

Amazon holds a 15-20% stake in Anthropic, which is preparing for a large IPO, potentially boosting Amazon's investment value.

Alphabet Inc Class C
GOOG
▲ PositiveCapitalrelevance

Alphabet holds about 14% of Anthropic, which is preparing for a large IPO, potentially boosting Alphabet's investment value.

Theme Impact 2

Off-coverage companies 2

AnthropicPrivate▲ Positive
Capitalrelevance

Anthropic filed for IPO, which is the subject of the article, signaling a path to public listing and potential value realization.

OpenAIPrivate± Mixed
relevance

Related news

Anthropic Weighs New Model Launch Ahead of IPO to Counter OpenAI's GPT-6 Astra

Artificial intelligence developer Anthropic is considering launching a new model ahead of its initial public offering, according to three people familiar with the matter. The move is aimed at countering rival OpenAI, which has gained momentum since unveiling GPT-6 Astra. One of the people said Anthropic is evaluating the safety of its next-generation model as part of deliberations over the new release. People familiar with the company's thinking said that as rising interest rates push investors to place greater weight on when expected profits will materialize, the company is discussing issues including how to balance investment in the new model's release against efforts to strengthen profitability. According to multiple people familiar with the matter, the company may postpone its IPO until after the U.S. midterm elections in November. Anthropic declined to comment.
Artificial Intelligence
ロイター·18mRead more →
2

OpenAI CEO Altman to Address AI Safety at UN Security Council Meeting

OpenAI CEO Sam Altman will speak about AI safety measures at a Security Council meeting next week, as world leaders gather in New York for the UN General Assembly. A company spokesperson confirmed the plan on the 18th, noting that the Security Council will hold a meeting on AI and international security on the 23rd. According to the spokesperson, Altman will discuss the need for international coordination and common safety standards, as well as the measures the company is taking. According to diplomatic sources, an Anthropic executive is also expected to attend the meeting, though this has not yet been finalized. Several AI industry executives have warned in recent weeks that AI could soon evolve autonomously and escape human control, and have called for a coordinated slowdown in development.
Artificial Intelligence
ロイター·1hRead more →
▲

UBS Flags AI Science Shift as Investment Theme After OpenAI Proof

UBS Wealth Management says artificial intelligence is moving beyond text generation into scientific research, opening investment opportunities across AI infrastructure, pharmaceuticals, nuclear fusion, industrial materials and utilities. The shift was highlighted by OpenAI's recent mathematical proof related to the Navier-Stokes equations, a centuries-old fluid dynamics problem and one of seven Millennium Prize Problems, which OpenAI tackled using 10,000 autonomous AI agents working in parallel for 88 hours before formalizing the proof with Lean, a system for machine-checked mathematical validation. In pharmaceuticals, multi-agent AI systems can simulate millions of protein variations in the cloud, and more than 170 AI-designed programs are already in development or clinical evaluation, including Phase III trials. In nuclear fusion, reinforcement-learning systems can predict plasma disruptions around 200 milliseconds before they occur and adjust magnetic coils thousands of times per second, while AI models in materials science can test millions of elemental combinations daily in search of properties for lighter, higher-density batteries, lower-heat computing hardware and potential room-temperature superconductors. The broader investment case centers on AI becoming a tool for automating scientific research rather than simply generating content, with companies exposed to AI infrastructure, pharmaceuticals, industrial materials and utilities positioned to benefit as these technologies move toward commercial applications.
GOOGLLYMSFTNVDAUBSG.SW
Biotech & Genomic Medicine ▲Artificial Intelligence ▲Fusion Energy ▲
Investing.com·3hRead more →
© 2026 MarketDXNews